Compare AstraZeneca plc (AZN) vs Docusign Inc (DOCU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Docusign Inc — how do they compare? AstraZeneca plc trades at $158 (market cap $248.14B), while Docusign Inc trades at $57.98 (market cap $11.33B). The key difference: AstraZeneca plc is far larger — about 21.9× Docusign Inc's market cap, and AstraZeneca plc pays a 2.01% dividend while Docusign Inc pays none. Which is the better fit depends on your goals.
| AZN | DOCU | |
|---|---|---|
Market Cap | $248.14B | $11.33B |
Sector | Health | Technology |
52-Week High | $209.48 | $85.01 |
52-Week Low | $147.06 | $41.75 |
Enterprise Value | $275.41B | $10.70B |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $161.91, up 0.3% on the day, amid mixed technical signals and strong fundamental performance. The stock exhibits a bearish technical trend with key support at $161 and resistance at $163, while recent earnings consistently beat expectations with Q2 2026 EPS of $2.63 versus $2.50 estimated. Revenue growth has been robust, climbing from $44.4B in 2022 to $58.7B in 2025, with a net income margin of 17.4% in 2025. Recent news centers on potential merger discussions with Bristol Myers Squibb, though reports on August 5, 2026, from Reuters indicate no current talks.
The outlook for AZN is cautiously optimistic, driven by solid profitability and analyst support, but tempered by merger-related volatility and a bearish technical setup. Investment opportunities lie in its high gross margin of 81.88% and positive earnings trajectory, while risks include integration challenges from any future acquisitions and market sensitivity to deal speculation. The stock's valuation at a P/E of 23.76 appears reasonable given its growth profile.
DOCU trades at $59.64, down 1.03% today but maintaining strong technical momentum with a bullish moving average signal. The company demonstrates robust fundamentals with revenue growth from $2.8B in 2024 to $3.0B in 2025 and impressive net income margin expansion to 35.87%. Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.09 surpassing the $0.994 estimate. Institutional activity shows mixed signals with some funds reducing positions while others increase exposure.
DOCU presents a compelling growth story with strong profitability metrics and consistent earnings beats, though valuation remains elevated at 38.53 P/E. The stock faces near-term resistance at $60-$62 levels with overbought RSI conditions. Analyst consensus leans cautious with 67.86% hold ratings, suggesting potential consolidation before further upside. Key risks include competitive pressures in e-signature space and execution challenges in maintaining current growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Docusign Inc
DocuSign offers the Agreement Cloud, a broad cloud-based software suite that enables users to automate the agreement process and provide legally binding e-signatures from nearly any device. The company was founded in 2003 and completed its IPO in May 2018.
Read more on DOCU →
